A summary of the phase III BREAK-3 trial comparing the BRAF inhibitor dabrafenib with the chemotherapy agent dacarbazine (DTIC).

Patients taking dabrafenib had an improved progression-free survival (PFS) of 2.4 months compared with patients receiving chemotherapy. Read more...

Melanoma Research Foundation

Donate Today

Every day the Melanoma Research Foundation works to make the fight against melanoma easier.
Your donation will help us support patients, fund research and advocate for the melanoma community.